References
- Tang MHY, Li TC, Lai CK, et al. Emergence of new psychoactive substance 2-fluorodeschloroketamine: Toxicology and urinary analysis in a cluster of patients exposed to ketamine and multiple analogues. Forensic Sci Int. 2020;312:110327
- Backberg M, Beck O, Helander A. Phencyclidine analog use in Sweden-intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project. Clin Toxicol. 2015;53(9):856–864.
- Davidsen AB, Mardal M, Holm NB, et al. Ketamine analogues: Comparative toxicokinetic in vitro-in vivo extrapolation and quantification of 2-fluorodeschloroketamine in forensic blood and hair samples. J Pharm Biomed Anal. 2020;180:113049
- Theofel N, Moller P, Vejmelka E, et al. A fatal case involving N-Ethyldeschloroketamine (2-Oxo-PCE) and venlafaxine. J Anal Toxicol. 2019;43(2):e2–e6.
- Rao SS, Wood DM, Dargan PI. Ketamine - epidemiology of misuse and patterns of acute and chronic toxicity. In: D.T. Yew (Ed.), Ketamine: Use and Abuse. Boca Raton: CRC Press, 2015. pp. 103–144.
- Frison G, Zamengo L, Zancanaro F, et al. Characterization of the designer drug deschloroketamine (2-methylamino-2-phenylcyclohexanone) by gas chromatography/mass spectrometry, liquid chromatography/high-resolution mass spectrometry, multistage mass spectrometry, and nuclear magnetic resonance. Rapid Commun Mass Spectrom. 2016;30(1):151–160.
- Tang MHY, Chong YK, Chan CY, et al. Cluster of acute poisonings associated with an emerging ketamine analogue, 2-Oxo-PCE. Forensic Sci Int. 2018;290:238–243.